Orexigen Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, announced completion of enrollment in NB-303 and NB-304, the final two Phase III clinical trials for Contrave, its lead obesity product candidate. Today's announcement marks the completion of patient enrollment for the full Contrave Phase III program, keeping Contrave on track for an NDA submission to the FDA in late 2009.
Read More...
[Source: Obesity / Weight Loss / Fitness News From Medical News Today - Posted by FreeAutoBlogger]
8 Easy Ways To Naturally Boost Your Testosterone Levels
0 comments:
Post a Comment